Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide added to standard induction chemotherapy for older or very poor-risk AML
NL-OMON39429Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (4 arms), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity and Complete remission rate. Started Jun 2010; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on NL-OMON39429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39429.